ストックスクリーナーアプリを入手
56.83
0.14%
0.08
Janux Therapeutics Inc (JANX) 最新ニュース
Wellington Management Group LLP Sells 29,436 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Buy" from Analysts - MarketBeat
State Street Corp Sells 40,056 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Barclays PLC - MarketBeat
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Scrip
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Janux Nets $350M in Stock Sale - San Diego Business Journal
Neo Ivy Capital Management Buys Shares of 20,674 Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Navigating 10 Analyst Ratings For Janux Therapeutics - Benzinga
Charles Schwab Investment Management Inc. Raises Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Polar Asset Management Partners Inc. Buys New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Point72 Asset Management L.P. Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - StockTitan
Revolution , Janux prep for next steps with follow-on cash - BioCentury
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to $350 Million Underwritten Public Offering - Wilson Sonsini
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
Janux Therapeutics prices $350M securities offering - MSN
Readystate Asset Management LP Acquires New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
JANX Stock Hits Record High on Prostate Cancer Study Data - MSN
Samsara BioCapital LLC Sells 22,526 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Janux Therapeutics, Inc. (NASDAQ:JANX) Stake Boosted by Janus Henderson Group PLC - MarketBeat
Janux Therapeutics Launches Massive $350M Public Offering to Fuel Clinical Pipeline Growth - StockTitan
Why Janux Therapeutics Crushed the Market Today - MSN
Janux Therapeutics Stock Hits 7-Month High On Prostate Cancer Drug Trial Data: Retail Confidence Spikes - MSN
Scotiabank lifts Janux Therapeutics shares target on strong position By Investing.com - Investing.com Canada
AstraZeneca’s new EVP of international amid China investigation; Janux’s $300M offering - Endpoints News
Janux Has A License To Thrill With 007’s Prostate Cancer Results - News & Insights
Janux Therapeutics CEO sells $1 million in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics Reports Promising Phase 2b Trial Results - Yahoo Finance
Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap - GuruFocus.com
Janux Therapeutics CEO sells $1 million in stock - Investing.com
Confidence in masked T cell engagers builds with Janux update - BioCentury
Janux Therapeutics share target lifted, buy rating held on strong trial data - Investing.com Canada
Health Care Down, But Near All-Time Highs, as Biotech Firms Gain -- Health Care Roundup - Marketscreener.com
Janux Therapeutics soars on clinical trial data for prostate cancer treatment candidate - Mugglehead
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride - Yahoo! Voices
Biotech Rockets 49% To Record High On 'Unprecedented' Results - Investor's Business Daily
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine - Yahoo Finance
Janux Therapeutics Announces Proposed Public Offering - Business Wire
Janux's T-cell engager data sparks buzz about possible Pluvicto challenger - FirstWord Pharma
Janux updates clinical results for JANX007, stock rated Outperform as sales estimate rises to $3B - Investing.com
Janux Therapeutics stock positioned for growth, Stifel raises PT with Buy rating - Investing.com
Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz - Yahoo Finance
Leerink boosts Janux Therapeutics shares target on trial data By Investing.com - Investing.com Nigeria
Janux's T-cell engager makes waves, again, with 'best-in-class' data drop: analyst - Fierce Biotech
Janux Therapeutics stock holds Buy rating, analyst sees potential By Investing.com - Investing.com Nigeria
Janux Therapeutics Stock Soars 63% on Prostate Cancer Drug Trial Results - Barron's
Janux impresses Wall Street with new prostate cancer drug results - BioPharma Dive
Leerink boosts Janux Therapeutics shares target on trial data - Investing.com
Janux Therapeutics stock holds Buy rating, analyst sees potential - Investing.com
Janux Therapeutics stock jumps as '007 shows high efficacy in HRPC, rating remains Overweight - Investing.com Canada
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Inkl
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):